Why the study?
Patients developing de novo heart-reactive antibodies after HF hospitalization face increased risk of adverse outcomes, prompting further investigation into the adaptive immune response, incident antibodies, and their relation to worsening cardiac function and prognosis.
Seroconversion to heart-reactive antibodies occurs early (within 6 weeks) after hospitalization for acute heart failure in a subgroup of patients, highlighting a potential adaptive immune response.
May support immune phenotyping in acute HF; leaves open prognostic and therapeutic implications pending validation.
No takes yet. Share an insight, caveat, or question.
Beyersdorf et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: